Search Results

Lisata Therapeutics, Inc. announced that the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1 (also known as “CEND-1”), Lisata’s lead product candidate, in combination with standard-of-care (“SoC”) chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (“mPDAC”).

On January 29th, the results of the phase II study on Qilu Pharmaceutical’s novel anticancer drug iparomlimab and tuvonralimab were published online in Signal Transduction and Targeted Therapy.

The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase -positive non-small cell lung cancer, have recently been featured in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

Recently, the results of the Phase I study for iparomlimab, developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journal Frontiers in Immunology.

The 2024 American Society of Clinical Oncology Annual Meeting convened from May 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format.

Data from Qilu Pharmaceutical’s clinical trial of its novel bifunctional antibody, QL1706 (iparomlimab and tuvonralimab), will be unveiled during a mini oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress 2023.

During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster presentation.

Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab, an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster presentation at the European Society for Medical Oncology Asia Congress 2023 taken place from December 1-3.

On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023.

August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical’s iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral presentation at the conference.